Vera Therapeutics to Participate at Upcoming Investor Conferences
MWN-AI** Summary
Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company based in Brisbane, California, announced its participation in several upcoming investor conferences aimed at showcasing its commitment to developing transformative treatments for serious immunological diseases. The management team will engage in a combination of presentations and one-on-one meetings to discuss the company's innovative pipeline.
The presentations will kick off at the TD Cowen 46th Annual Health Care Conference on March 3, 2026, where a fireside chat is scheduled for 11:10 a.m. ET in Boston, MA. Investors unable to attend live can access a replay via the company’s website for up to 90 days post-event. This will be followed by participation in one-on-one meetings at the Barclays 28th Annual Global Healthcare Conference in Miami on March 10, 2026, and the Jefferies 2026 Biotech on the Beach Summit on March 11, 2026.
Vera Therapeutics is focused on creating breakthrough therapies to address the root causes of diseases such as immunoglobulin A nephropathy (IgAN) and lupus nephritis, with its lead product candidate being atacicept. This innovative treatment, administered as a subcutaneous injection, targets B cell activity to reduce autoantibodies. Additionally, the company has an exclusive license with Stanford University for VT-109, a next-generation fusion protein, and is also working on MAU868, a monoclonal antibody intended to neutralize BK virus infections in kidney transplant recipients.
These initiatives underscore Vera Therapeutics' dedication to redefining standards of care in immunological disease treatment. For further details, investors and interested parties are encouraged to visit their website at www.veratx.com.
MWN-AI** Analysis
With Vera Therapeutics (NASDAQ: VERA) set to participate in pivotal investor conferences in March 2026, this represents a strategic moment for investors to reassess their positions within the company. The clinical-stage biotechnology firm is focused on innovative treatments for serious immunological diseases, with their lead candidate, atacicept, at the forefront of its potential breakthroughs.
Vera Therapeutics is scheduled to engage in one-on-one meetings and present at high-profile events, such as the TD Cowen 46th Annual Healthcare Conference in Boston and the Jefferies 2026 Biotech on the Beach Summit in Miami. These conferences provide a platform for management to communicate the company’s progress, pipeline advancements, and research insights, which can significantly influence investor sentiment and stock performance.
Investors should closely monitor the dialogue surrounding atacicept, which targets autoantibodies implicated in autoimmune diseases like IgA nephropathy (IgAN) and lupus nephritis. The broader implications of atacicept's success could enhance Vera’s market positioning and drive long-term growth. Additionally, the company's promising pipeline—including VT-109 and MAU868—positions it well for expansion across B-cell-mediated diseases and the immunocompromised population.
Moreover, Vera holds exclusive global rights to these candidates, emphasizing its autonomous path to commercialization. As upcoming announcements and potential interim clinical trial results surface post-conferences, they could significantly impact stock trajectories.
Despite the inherent risks characterized by regulatory uncertainties and market dynamics, Vera Therapeutics' recent engagements could catalyze interest and investment, especially within the biotech sector, which remains fertile ground for disruptive innovations. Current and prospective investors should remain vigilant, attending these events or reviewing summaries to seize opportunities or mitigate risks.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
BRISBANE, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s management team will present and participate in one-on-one meetings at upcoming investor conferences.
Investor Conference Details:
- TD Cowen 46th Annual Health Care Conference
Format: Fireside chat and 1x1 investor meetings
Webcast: https://event.summitcast.com/view/9z5g2VrV6e6rbCqQgDRoHA/Etdv38YcyjD9fFRQNSrAUo
Date: Tuesday, March 3, 2026
Time: 11:10am ET
Location: Boston, MA
- Barclays 28th Annual Global Healthcare Conference
Format: 1x1 investor meetings
Date: Tuesday, March 10, 2026
Location: Miami, FL
- Jefferies 2026 Biotech on the Beach Summit
Format: 1x1 investor meetings
Date: Wednesday, March 11, 2026
Location: Miami, FL
A replay of the TD Cowen fireside chat will be available for 90 days and can be accessed by visiting the “Investor Calendar” section of the Vera Therapeutics website.
About Vera Therapeutics
Vera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera Therapeutics’ mission is to advance treatments that target the source of disease in order to change the standard of care for patients. Vera Therapeutics’ lead product candidate is atacicept, a fusion protein self-administered at home as a subcutaneous once weekly injection that blocks both BAFF and APRIL, which stimulate B cells to produce autoantibodies contributing to certain autoimmune diseases, including IgAN and lupus nephritis. Beyond IgAN, Vera Therapeutics is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove clinically meaningful. In addition, Vera Therapeutics holds an exclusive license agreement with Stanford University for a novel, next generation fusion protein targeting BAFF and APRIL, known as VT-109, with wide therapeutic potential across the spectrum of B-cell-mediated diseases. Vera Therapeutics is also evaluating development of MAU868, a monoclonal antibody designed to neutralize infection with BK virus, which can have devastating consequences in kidney transplant recipients. Vera Therapeutics retains all global developmental and commercial rights to atacicept, VT-109 and MAU868. For more information, please visit www.veratx.com.
Forward-looking Statements
Statements contained in this press release regarding matters, events or results that may occur in the future are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, Vera Therapeutics’ plans, commitments, aspirations and goals related to its product candidates. Words such as “anticipate,” “believe,” “expect,” “may,” “plan,” “potential,” “will” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Vera Therapeutics’ current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks related to the regulatory approval process, results of earlier clinical trials may not be obtained in later clinical trials, preliminary results may not be predictive of topline results, risks and uncertainties associated with Vera Therapeutics’ business in general, the impact of macroeconomic and geopolitical events, and the other risks described in Vera Therapeutics' filings with the U.S. Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Vera Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
For more information, please contact:
Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
jallaire@lifesciadvisors.com
Media Contact:
Debra Charlesworth
Vera Therapeutics
415-854-8051
corporatecommunications@veratx.com
FAQ**
How does Vera Therapeutics Inc. VERA plan to position atacicept in the market compared to existing treatments for autoimmune diseases like IgAN and lupus nephritis?
What key milestones should investors expect from Vera Therapeutics Inc. VERA in the coming year regarding the clinical development of its product candidates?
Can you elaborate on the strategic advantages of Vera Therapeutics Inc. VERA’s exclusive license agreement with Stanford University for the VT-109 fusion protein?
What measures is Vera Therapeutics Inc. VERA taking to mitigate risks associated with the regulatory approval process for its lead candidate, atacicept?
**MWN-AI FAQ is based on asking OpenAI questions about Vera Therapeutics Inc. (NASDAQ: VERA).
NASDAQ: VERA
VERA Trading
0.75% G/L:
$39.05 Last:
354,658 Volume:
$39.14 Open:
